01Class IV is a statute line, not a street ranking
PROVIGIL labeling states that the tablets contain modafinil, a Schedule IV controlled substance. That sentence does not change because the tablet is 100 mg instead of 200, or because someone on a forum called it 'just a wake helper.'
Schedule IV sits below III and II in US federal ranking. It still means prescription control, refill rules that vary by jurisdiction, and diversion liability if you hand a tablet to a coworker. It is not a moral score of how 'addictive' a night felt.
Abuse potential was studied less like amphetamine marketing and more like a wake drug with psychiatric and dermatologic risks. Overdose reports in the PI include agitation, insomnia, and hemodynamic bumps at multiples of the daily dose. None of that makes leftover 100 mg tablets community property.
02Rash in the first weeks is not a cosmetic complaint
Rare adult and pediatric cases of SJS, TEN, and DRESS sit in postmarketing language. Pediatric trials that looked at ADHD - an unapproved use - saw serious rash including a possible SJS case. Modafinil is not approved in children for any indication.
Nearly all serious rashes began within one to five weeks. Isolated cases arrived after months. Duration of therapy is a poor predictor once a rash appears. Stop and call. Do not finish the blister to 'not waste a controlled script.'
Angioedema and anaphylaxis are separate stop rules. A schedule class does not change those.
03An import blister does not cancel the schedule
Overseas packs that stamp a different brand still contain modafinil if the INN line says so. US schedule talk still describes the molecule. Customs and national pharmacy law decide what happens to the box. This desk will not coach an import.
FDA-listed generic modafinil exists in US pharmacies. That path is not the same as a gray blister. Read label literacy before anyone equates logos.
Nora Lindqvist will not invent a cash price for Provigil or for an import brand. Price talk without a dated pharmacy quote is how fake coupons start.
04How early-refill stories turn into diversion stories
Lost-in-the-gym and shared-with-a-colleague are the two early-refill plots that show up in desk mail. Both are reasons for a clinician conversation, not a silent extra bottle.
Counting leftover 100 mg tablets in a workplace chat is already a diversion trail. Delete the thread and fix the roster.
A parent who 'just wants one for exam week' is asking for an unapproved pediatric use plus a controlled transfer. The answer is no, twice.
05A 100 mg tablet is not a school-performance script
Modafinil is not approved for any pediatric indication. ADHD trials in children saw serious rash, including a possible SJS case among hundreds exposed. That history is part of why the pediatric door stayed shut.
A parent who wants 'just one 100 mg for exams' is asking for an unapproved use and a controlled transfer. The answer is no on both counts.
Adult leftover tablets in a teenager's backpack are a diversion story waiting for a school nurse. Keep the labeled bottle with the adult who owns the indication.
If a sixteen-year-old has genuine hypersomnia, that is a specialist evaluation, not a borrowed wake tablet from a night-shift parent.
Auto-induction talk shows up in the PI as sometimes-lower troughs after multiple weeks, judged of minimal clinical significance, plus a sulfone metabolite with a long half-life near 40 hours. None of that lifts the schedule from a 100 mg tablet or licenses a workplace jar.
Severe chronic renal failure did not much change parent modafinil in a 200 mg single-dose study, but the inactive acid metabolite rose nine-fold. Kidney failure is not a reason to treat 100 mg as uncontrolled. It is a reason to keep the labeled bottle in one person's name.
06What a Stockholm clinic chart should still document
Indication (SWD, narcolepsy, OSA add-on), tablet strength, swallow clock, contraceptive plan, rash teaching, and that the person was told not to share. If the local schedule name differs, write both the US C-IV fact and the local rule.
Psychiatric history: mania, psychosis, severe anxiety. Wake drugs can unmask those. A clean diversion history does not erase that risk.
Mail [email protected] for editorial questions about this caveat. Do not send passport scans or leftover-tablet photos to that inbox.
07High-dose study swallows are not a workplace protocol
The PI records protocol doses from 1000 to 1600 mg a day in a small group, and two intentional overdoses at 4000 and 4500 mg in foreign depression studies. Those subjects did not produce a surprise life-threatening pattern in that write-up. They also did not create a 'safe high' for a night desk.
Reported high-dose effects included agitation, insomnia, and hemodynamic bumps. Anxiety, tremor, palpitations, and sleep disruption showed up too. None of that is a reason to pocket extra 100 mg tablets.
A workplace bottle 'for emergency wakefulness' needs a formulary and a prescriber. Leftover patient tablets in a staff drawer are diversion, not preparedness.
This despatch will not invent a milligram ceiling for off-label crunch weeks. The labeled adult doses stay 200 mg for the named indications, with 400 mg as a studied but not consistently better option.
08Psychiatric unmasking is not a schedule footnote
Anxiety, mania, and hallucinations sit in the wake-drug warning set. A clean diversion history does not cancel those. A 100 mg start can still unmask a bipolar story that nobody wrote down.
New grandiosity or a first break after a week of nights plus a tablet is a stop-and-call, not a reason to add a second 100 mg 'to finish the roster.'
Document the psychiatric screen at the same visit as the C-IV teaching. Splitting those conversations is how the schedule line becomes the only line anyone remembers.
09Leftover 100 mg tablets are not a staff snack
Sharing a controlled wake tablet is diversion, even if the night roster is brutal and the recipient 'has a diagnosis too.' Diagnoses are not transferable. Rash risk is not transferable. Psychiatric reactions are not transferable.
Keeping a kitchen jar of mixed 100 mg and 200 mg tablets from different fills is how a later clinician loses the day-count. One labeled bottle, one person, one prescriber.
Travel across borders with a C-IV needs the prescription paperwork that country asks for. This desk does not write travel letters.
Diversion patterns in desk mail
- Do not post leftover counts in a workplace chat
- Do not refill early because a friend is 'borrowing' (that is a new prescription problem)
- Import packs sold as Modalert are a different regulatory story: see Modalert vs Provigil
10Travel paperwork is not a letters-desk product
Crossing a border with a C-IV needs the prescription copy and any import certificate that country asks for. This inbox will not draft those papers or guess a customs outcome.
Leaving 100 mg tablets in a hotel bathroom 'for next trip' is how someone else's child finds a controlled wake drug. One labeled bottle, one person, one return flight.
If the only pack you can show is an overseas logo, you have a literacy problem and a class problem at once. Read the compare and literacy despatches before you treat the suitcase as a pharmacy.
11Why 100 mg still counts as controlled
Both marketed tablet strengths carry the C-IV mark on US labeling. Debossing that says 100 MG is a strength cue, not a lighter legal class.
People ask whether a 'low' start is somehow OTC-adjacent. It is not. A clinician may choose 100 mg for hepatic half-dose math or for tolerability. The schedule sticker stays.
Swedish readers should not import US schedule talk as Swedish pharmacy law. Ask the dispensing pharmacist which national rules apply. This despatch annotates the US PI because that is the label we read.
12Steroidal cover can fail for a month after the last tablet
Modafinil can induce CYP3A4/5 pathways enough to lower ethinyl estradiol and other steroidal contraceptives. The caution runs through treatment and for one month after discontinuation. Depot and implants are in that counseling sentence.
A person who stops a 100 mg tablet because of insomnia and then relies on the same pill pack without a backup is reading only half the label.
Midazolam, triazolam, and cyclosporine also sit on the CYP3A4/5 caution. Put the whole roster on the table, including a borrowed sedative taken 'just for the flight.'
13Seal on the controlled-substance strip
Treat 100 mg as controlled because the molecule is controlled. Teach rash and contraceptive failure with the same breath as the schedule line.
Return to the modafinil letter for indications and the SWD clock. This postscript is only the caveat.
Early-refill plots (lost-in-the-gym, shared-with-a-colleague) belong in the chart, not in a workplace chat. Counting leftover 100 mg tablets in a group thread is already a diversion trail.
Swedish pharmacy law is not US C-IV by another name. Ask the dispensing pharmacist which national rule applies, then still teach the US PI facts this desk annotates. A smaller milligram stamp still carries the class.
Sources and how this letter was sealed
- FDA PI, PROVIGIL: Drug Abuse and Dependence (C-IV); Warnings 5.1 (rash); 5.5 (contraceptives); Dosage 2.
- DailyMed PROVIGIL
- Controlled Substances Act listing for modafinil as referenced in the PI.
Method in brief: open primary sources, annotate against the current FDA label, countersign by Dr. Nora Lindqvist, MD, then seal with a dated review. Full walk-through on the method page and editorial standards.
How to cite this page - Vancouver style
Juvia Pharma Despatch Desk. Schedule IV still applies to a 100 mg tablet [Internet]. Stockholm: Juvia Pharma; 21 August 2026 [cited 2026 Aug 21]. Available from: https://juviapharma.com/postscripts/provigil-schedule-caveat/
